Infertility Clinical Trial
— LoGoOfficial title:
A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction
This is a prospective, multicenter, open-label, comparative and parallel-group study of ovulation induction evaluating tailoring of Recombinant follicle stimulating hormone (FSH) treatment using the Gonal-f® prefilled pen in World Health Organization (WHO) Type 2 anovulatory subjects who have previously failed to conceive with clomifene treatment.
Status | Completed |
Enrollment | 26 |
Est. completion date | March 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 37 Years |
Eligibility |
Inclusion Criteria: - Subjects eligible for ovulation induction treatment, where monofollicular development is the desired treatment outcome and the dose schedule outlined in the protocol is deemed appropriate - Premenopausal female subjects, aged between 18 and 37 years inclusive - Subjects desirous of pregnancy/willing to conceive - Subjects who are infertile due to chronic anovulation demonstrated by cycle duration of greater than 35 days. - Subjects who have been treated with clomifene citrate therapy, according to standard site practice, and have failed to ovulate and/or conceive - Subjects with follicle stimulating hormone (FSH) and prolactin (PRL) serum values within the normal range in the early follicular phase - Subjects with an overall total antral follicle count greater than 10 (of follicle size greater than or equal to 2 millimeter [mm] and less than 11 mm) (that is, total between both ovaries) - Subjects with at least one patent tube, as documented by recent (within 2 years before treatment assignment) hysterosalpingography (HSG) or hysterosalpingo contrast sonography (HyCoSy) - Subjects with normal uterine cavity, as documented by recent (within 2 years before treatment assignment) hysteroscopy, HSG or ultrasound scan - Subjects with body mass index (BMI) greater than 20 and less than or equal to 32 kilogram per square meter (kg/m^2) (BMI is equal to body weight [kilogram {kg}] divided by Height * Height [square meter {m^2}]) - Subjects with negative cervical Papanicolaou (PAP) test conducted according to national guidelines and/or standard site practice - Male partners of female subjects with sperm compatible with non-assisted fertilization or availability of donor sperm, as confirmed by the Investigator - Subjects who are willing and able to comply with protocol requirements and have provided written, informed consent Exclusion Criteria: - Subjects with history of hypersensitivity to the investigational medicinal product (IMP) (active substance follitropin alpha, FSH, or to any of the excipients of Gonal-f®) or any other drug used in the trial (that is, Ovitrelle) - Subjects with ovarian enlargement or ovarian cyst unrelated to Polycystic Ovary Syndrome (PCOS), and of unknown origin on ultrasound - Subjects with evidence of diminished ovarian reserve (cycle length less than 26 days; FSH above the upper limit of local serum FSH values, total antral follicle count [AFC] in both ovaries less than 10) - Subjects with uterine pathology/abnormalities, which in the opinion of the Investigator could impair pregnancy evolution - Subjects who have undergone three or more previous miscarriages - Subjects with any previous extrauterine pregnancy - Pregnant or lactating female subjects - Subjects with abnormal gynecological bleeding of unknown etiology. - Subjects with previous history of severe ovarian hyper stimulation syndrome (OHSS) (after clomifene treatment) - Subjects who have evidence of current or previous pelvic inflammatory disease before treatment assignment - Subjects with tumors of the hypothalamus and pituitary gland - Subjects with ovarian, uterine or mammary carcinoma - Subjects treated with clomifene citrate or gonadotropins within 1 month of the screening evaluation - Subjects with any medical condition which, in the opinion of the Investigator, would prevent an effective response, such as primary ovarian failure, or malformations of the reproductive organs incompatible with pregnancy - Subjects with any medical condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug - Subjects with any clinically significant systemic disease (for example, insulin-dependent diabetes) or any contraindication to being pregnant and/or carrying a pregnancy to term - An active substance abuser - Known infection with human immunodeficiency virus (HIV), Hepatitis B or C virus in the trial subject or her male partner - Subjects who are currently participating in another clinical trial - Subjects who are unable to give written informed consent |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Ireland | Research Site | Cork | |
Ireland | Research Site | Galway | |
United Kingdom | Research Site | Cambridge | |
United Kingdom | Research site | Cheshunt | |
United Kingdom | Research Site | Derby | |
United Kingdom | Research Site | Edinburgh | |
United Kingdom | Research Site | Glasgow | |
United Kingdom | Research site | London |
Lead Sponsor | Collaborator |
---|---|
Merck KGaA |
Ireland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of cycles with monofollicular development that is, only one follicle greater than or equal to 17 millimeter and no other follicles greater than or equal to 14 millimeter | up to 4 weeks | No | |
Secondary | Percentage of cycles with bifollicular development that is, only two follicles greater than or equal to 17 millimeter | up to 4 weeks | No | |
Secondary | Percentage of cycles with multifollicular development that is, three or more follicles greater than or equal to 14 millimeter | up to 4 weeks | No | |
Secondary | Percentage of ovulatory cycles | up to 42 days post human chorionic gonadotrophin (hCG) administration | No | |
Secondary | Percentage of cycles wherein hCG was not administered | up to 4 weeks | No | |
Secondary | Percentage of cycles resulting in clinical pregnancy | 35-42 days post hCG administration | No | |
Secondary | Number of multiple pregnancy | 35-42 days post hCG administration | No | |
Secondary | Number of fetuses | 35-42 days post hCG administration | No | |
Secondary | Number of miscarriages after confirmation of clinical pregnancy | 35-42 days post hCG administration | No | |
Secondary | Number of subjects with Ovarian Hyper Stimulation Syndrome (OHSS) | up to 42 days post hCG administration | Yes | |
Secondary | Duration of Recombinant Follicle Stimulating Hormone (rFSH) stimulation | up to 4 weeks | No | |
Secondary | Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH) administered per cycle | up to 4 weeks | No | |
Secondary | Change from Baseline in Anti-Mullerian Hormone (AMH) levels at Week 4 | Baseline and Week 4 | No | |
Secondary | Testosterone levels | Baseline | No | |
Secondary | Sex Hormone Binding Globulin (SHBG) levels | Baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A |